INTRODUCTION
Randomized controlled trials (RCTs) have historically been considered the primary source of evidence to support decision-making in market access and reimbursement. However, thanks to significant progress in capturing data through computerized systems and making these data available, real-world evidence (RWE) has been increasingly considered by manufacturers and payers. Despite initiatives and research worldwide to promote the use of RWE in healthcare decision-making, an overview of its use over a product lifecycle, its strengths and pitfalls, and how it is perceived from a regulatory and payer perspective will provide a better understanding of what RWE is and how it can support decision-making.
Characterization of real-world data and evidence RWD can be defined as raw information used for decision-making that are not collected in conventional RCTs, while RWE is the organization of RWD to facilitate the decision-making process. The ISPOR Real-World Data Task Force defined 6 sources of RWD. Various statistical methods are already available to address the pitfalls in RWD, such as adjustment for selection bias and confounding effect using multivariate modelling, propensity scoring or instrumental variables. Missing data can also be addressed using multiple imputation methods, or maximum likelihood modelling. In addition, several RWD initiatives aim at improving the standardization of the information captured, providing more robust data quality assurance processes and overcoming methodological issues.
3, 4, 5
The role of RWE throughout the product lifecycle (figure 1)
From both the payer and the manufacturer perspective, RWE can:
• Improve disease knowledge (e.g. identify unmet needs)
• Support the positioning of a product and identify patients with the greatest benefits • Provide evidence and fill data gaps for HTA submissions • Improve scientific community knowledge • Inform optimal decision-making 
HTA perspectives on RWE
We reviewed 73 guidelines from HTA agencies and governmental authorities and only found 10 that provided a description of their views on RWD in English. All 10 of them stated that RWE is a 'nice to have' as a supplement for evidence in economic evaluations, but is not required. More specifically, they acknowledged the usefulness of RWD in:
• Sourcing country-specific resource use and costs • Estimating natural history and baseline risks in actual clinical practice, therefore supporting the extrapolation of RCT data and facilitating modelling beyond the time horizon of the RCT • Sourcing country-specific QoL data • Estimating long-term outcomes, especially treatment-related (i.e. true effectiveness and safety) • Sourcing true compliance estimates • Identifying real-world treatment pathways and comparators • Providing evidence for a patient population that is broader than that of the RCT, hence enhancing the generalizability and transferability of the results (e.g. patient with co-morbidities or concomitant therapies) • Further validating model assumptions and performance in a realworld setting
As expected, all these guidelines also emphasized the risk of bias and the requirements fort a rigorous appraisal of the quality and the design.
AIM
This research is an attempt at characterizing RWE, summarizing its inherent benefits and challenges, and discussing where it can be used over a product lifecycle to facilitate market access and reimbursement.
METHODS
We reviewed the literature as well as guidelines from health technology assessment (HTA) agencies to characterize RWE and its increasing role in decision-making, and to understand HTA perspectives on RWE. We also mapped the use of RWE on the product lifecycle, to assess how the patient, the payer and the industry can benefit from RWE.
DISCUSSION
RWE is becoming an inherent component of the overall evidence sought after to support market access and reimbursement, both from the manufacturer and the payer perspective. Using RWE is still at an early stage, where concerns about its validity and applicability are raised, but much progress has been made regarding its acknowledgement during the last decade or so.
Despite the lack of randomization and other quality factors inherent to RWD observational design, they provide information that is critical to support decision-making by enhancing the understanding of the real world patients live in.
In parallel with RWD becoming increasingly available and wealthy of information (e.g. national registries, large networks of clinical practices and hospitals), initiatives around the standardization, validation and analytical methodologies are also improving the transparency and usability of such data.
CONCLUSION
The golden age of RWE has yet to come and significant research is still needed to ensure RWD can be used in a meaningful manner. However, a wealth of health data captured every day is already available and can improve decision-making in healthcare despite their limitations.
